Glenmede Trust’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Glenmede Trust’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-300	Closed	-$6K	–	2796
2016 Q4	$6K	Sell	300 -700	-70%	-$13.7K	﹤0.01%	2212
2016 Q3	$22K	Hold	1,000	–	–	﹤0.01%	1912
2016 Q2	$23K	Hold	1,000	–	–	﹤0.01%	1856
2016 Q1	$20K	Hold	1,000	–	–	﹤0.01%	1826
2015 Q4	$51K	Hold	1,000	–	–	﹤0.01%	1557
2015 Q3	$42K	Buy	+1,000	New	+$48.3K	﹤0.01%	1646

Other funds holding PTLA

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Glenmede Trust's PTLA Position: Q1 2017 in Review

Glenmede Trust sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2017, closing a stake of 300 shares — an estimated $6K sold.

Glenmede Trust first reported a position in PTLA in Q3 2015 and held it in 6 quarters. The position peaked at $51K in Q4 2015. 180 funds tracked by Wall St. Rank hold PTLA as of Q1 2017.

Glenmede Trust reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Glenmede Trust sold 300 Portola Pharmaceuticals, Inc. shares in Q1 2017, an estimated $6K.
Glenmede Trust first reported a position in Portola Pharmaceuticals, Inc. in Q3 2015 and held it in 6 quarters.
Glenmede Trust's Portola Pharmaceuticals, Inc. position peaked at $51K in Q4 2015.
180 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2017.

Based on Glenmede Trust's 13F filing for Q1 2017, filed 15 May 2017.